PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
8165.71%
Net income growth of 8165.71% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would note a slight edge that could grow if sustained.
86.48%
D&A growth of 86.48% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question intangible or new expansions driving that cost difference.
-212289.86%
Deferred tax shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see potential advantage if actual tax outflows do not spike.
-47.10%
SBC declines yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a near-term advantage in less dilution unless new hires are needed.
69.98%
Working capital of 69.98% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would check if expansions or cost inefficiencies cause that difference.
155.25%
AR growth of 155.25% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or more relaxed credit if revenue is not matching it.
-2448.29%
Inventory shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a working capital edge if sales hold up.
-12566.83%
AP shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see better immediate cost coverage if top-line remains intact.
1768.63%
Growth of 1768.63% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or unusual one-time factors behind the difference.
-143.57%
Other non-cash items dropping yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a short-term advantage if real fundamentals remain intact.
189.60%
CFO growth of 189.60% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would see a small edge that may compound with consistent execution.
45.39%
CapEx growth of 45.39% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or upgrades behind the difference.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
292.16%
Growth of 292.16% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss questions intangible or special projects explaining that difference.
-87.26%
Reduced investing yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman sees potential advantage in near-term liquidity if revenue remains stable.
No Data
No Data available this quarter, please select a different quarter.
-96.78%
We reduce issuance yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman might see an advantage in preserving per-share value unless expansions are neglected.
No Data
No Data available this quarter, please select a different quarter.